Swiss healthcare company Galenica reported a 5.5% increase in 2025 sales, reaching a record CHF 4.14 billion. This growth was driven by contributions from all business segments, with the company reaffirming its EBIT growth target of 10-12%. The pharmacy network expanded to 381 locations, including acquisitions, while the Pharmacies Omni-Channel division saw a 4.9% increase in sales, with organic growth at 3.3%. This performance reflects a slight advantage over the market growth for inpatient pharmacies.

Galenica's CEO, Marc Werner, attributed the success to the company's broad-based positioning and high integration within the network. The demand for consultations increased nearly 29%, with the pharmacy network providing 368,000 fee-based healthcare services, including 93,000 vaccinations. The integration of these services into insurance models by KPT and Helsana, effective January 1, allows patients to receive reimbursements.

The Products & Brands division recorded a 6.2% increase in sales to CHF 158 million in the Swiss consumer healthcare market. However, the export business declined 12.6% to CHF 36.2 million due to one-time effects in 2024. The September acquisition of Labor Team added a new Diagnostics business area, contributing CHF 40.7 million to the group's sales. The Services & Production area grew by 4%, with contributions from Bichsel, Lifestage, and Medifilm units.

Galenica's performance underscores its strong market position and strategic focus on integrated healthcare solutions. Investors will watch for continued growth in pharmacy services and the impact of new business segments, especially in diagnostics. The company's commitment to maintaining dividends and expanding its network suggests confidence in future performance.